[Articles] Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

Nivolumab combined with ipilimumab and nivolumab monotherapy are active in melanoma brain metastases. A high proportion of patients achieved an intracranial response with the combination. Thus, nivolumab combined with ipilimumab should be considered as a first-line therapy for patients with asymptomatic untreated brain metastases.

Source: The Lancet Oncology - March 27, 2018 Category: Cancer & Oncology Authors: Georgina V Long, Victoria Atkinson, Serigne Lo, Shahneen Sandhu, Alexander D Guminski, Michael P Brown, James S Wilmott, Jarem Edwards, Maria Gonzalez, Richard A Scolyer, Alexander M Menzies, Grant A McArthur Tags: Articles Source Type: research